PL363431A1 - The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders - Google Patents

The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders

Info

Publication number
PL363431A1
PL363431A1 PL01363431A PL36343101A PL363431A1 PL 363431 A1 PL363431 A1 PL 363431A1 PL 01363431 A PL01363431 A PL 01363431A PL 36343101 A PL36343101 A PL 36343101A PL 363431 A1 PL363431 A1 PL 363431A1
Authority
PL
Poland
Prior art keywords
copolymer
treatment
nervous system
central nervous
system disorders
Prior art date
Application number
PL01363431A
Other languages
Polish (pl)
Inventor
Wee V. Yong
Sophie Chabot
Original Assignee
Teva Pharmaceuticals Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals Industries, Ltd. filed Critical Teva Pharmaceuticals Industries, Ltd.
Publication of PL363431A1 publication Critical patent/PL363431A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL01363431A 2000-06-05 2001-06-05 The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders PL363431A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58752300A 2000-06-05 2000-06-05
PCT/US2001/018248 WO2001093828A1 (en) 2000-06-05 2001-06-05 The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders

Publications (1)

Publication Number Publication Date
PL363431A1 true PL363431A1 (en) 2004-11-15

Family

ID=24350145

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01363431A PL363431A1 (en) 2000-06-05 2001-06-05 The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders

Country Status (9)

Country Link
EP (1) EP1292279A4 (en)
JP (1) JP2003535118A (en)
AU (2) AU7528001A (en)
CA (1) CA2411536A1 (en)
HU (1) HUP0302333A3 (en)
IL (1) IL153236A0 (en)
PL (1) PL363431A1 (en)
WO (1) WO2001093828A1 (en)
ZA (1) ZA200210084B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (en) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Treatment of Crohn's disease with copolymer 1 and polypeptides
IL141021A0 (en) 1998-07-23 2002-02-10 Yeda Res & Dev Treatment of autoimmune conditions with copolymer 1 and related copolymers
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
US7429374B2 (en) 2001-12-04 2008-09-30 Teva Pharmaceutical Industries, Ltd. Process for the measurement of the potency of glatiramer acetate
HRP20160455T1 (en) 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, their compositions and methods for their preparation, and their uses
NZ598661A (en) 2009-08-20 2013-02-22 Yeda Res & Dev Low frequency glatiramer acetate therapy
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
CA2814500A1 (en) 2010-10-11 2012-04-19 Teva Pharmaceutical Industries Ltd Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
HK1200274A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
HK1213830A1 (en) 2012-10-10 2016-07-15 Teva Pharmaceutical Industries Ltd. Biomarkers predictive for clinical response for glatiramer acetate
UY35790A (en) 2013-10-21 2015-05-29 Teva Pharma GENETIC MARKERS THAT PREACH THE RESPONSE TO THE GLATIRAMER ACETATE
US10166253B2 (en) 2014-08-29 2019-01-01 Region Midtjylland Positively charged co-polymers for use as antimicrobial agents
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
CN106924175B (en) * 2015-12-29 2020-07-03 深圳翰宇药业股份有限公司 Pharmaceutical composition for treating multiple sclerosis
KR102425326B1 (en) 2016-05-20 2022-07-25 세다르스-신나이 메디칼 센터 Methods for treating or preventing Alzheimer's disease and related conditions
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN109982712A (en) 2016-08-31 2019-07-05 Mapi医药公司 Depot system containing glatiramer acetate
CN110382052A (en) 2017-03-26 2019-10-25 Mapi医药公司 The copaxone store system of multiple sclerosis for therapeutic advance type form
CN115151271A (en) * 2020-09-27 2022-10-04 长沙英奈发药业有限公司 Application of glatiramer acetate in preparation of Abeta 42 toxicity inhibitor and scavenger

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
GB9411292D0 (en) * 1994-06-06 1994-07-27 Teva Pharma Pharmaceuticals compositions
US5665764A (en) * 1995-06-02 1997-09-09 Warner-Lambert Company Tricyclic inhibitors of matrix metalloproteinases
IL119989A0 (en) * 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
JP4328050B2 (en) * 2000-01-20 2009-09-09 イエダ リサーチ アンド デベロップメント カンパニー リミテッド Use of Copolymer 1, related peptides and polypeptides and T cells treated with them for neuroprotective therapy
EP1294390B1 (en) * 2000-06-07 2006-01-04 YEDA RESEARCH AND DEVELOPMENT CO., Ltd. The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotection from glutamate toxicity

Also Published As

Publication number Publication date
CA2411536A1 (en) 2001-12-13
IL153236A0 (en) 2003-07-06
HUP0302333A3 (en) 2005-07-28
WO2001093828A1 (en) 2001-12-13
EP1292279A4 (en) 2005-01-12
AU2001275280B2 (en) 2006-03-16
EP1292279A1 (en) 2003-03-19
JP2003535118A (en) 2003-11-25
HUP0302333A2 (en) 2003-11-28
ZA200210084B (en) 2003-12-12
AU7528001A (en) 2001-12-17

Similar Documents

Publication Publication Date Title
IL153236A0 (en) The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
HUP0100069A3 (en) 4(3)substituted-4(3)-aminomethyl-pyran, or -thiopyran-piperidine derivatives, their preparation and their use in the treatment of neurological disorders
HUP0004439A3 (en) 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
AU9112201A (en) Pulmonary delivery in treating disorders of the central nervous system
HUP0100786A3 (en) Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them
IL151946A0 (en) 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
HUP0401023A3 (en) Use of flibanserin in the treatment of sexual disorders
IL187512A0 (en) Use of (s,s)-reboxetine in the treatment of pain conditions and incontinence
EP0924983A4 (en) S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
AU2001266152A1 (en) Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
ZA97741B (en) Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders.
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
IL160018A0 (en) Isoxazolopyridinones and use thereof in the treatment of parkinson's disease
GB0015228D0 (en) Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders
AU1591902A (en) Chemokine mutants in the treatment of multiple sclerosis
EP1079764A4 (en) The treatment of sexual dysfunction in certain patient groups
HUP0301553A3 (en) Pharmaceutical compositions and their use for treating neurological disorders
AU2002226060A1 (en) Compositions containing gangliosides for use in the treatment of skin disorders
IL129460A0 (en) Use of lofexidine in the treatment of behavioral disorders
AU2002210763A1 (en) Use of 1-ebio in the treatment of bipolar disorders
PL351554A1 (en) Osanetant in the treatment of mood disorders
HUP9902802A3 (en) Pyridyl- and pyrimidyl-piperazines in the treatment of substance abuse disorders
AU6330300A (en) Use of interleukin-6 in treatment of obesity and/or obesity associated disorders
AU2001292500A1 (en) 1,2,5,10-tetrahydropyridazino(4,5-b)quinoline-1,10-diones and their use for the treatment of pain

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)